Minisymposium: Biomarkers in Drug Discovery – How to Predict for Success in the Clinic

The SciLifeLab Drug Discovery and Development platform and AstraZeneca jointly welcome you to Biomarkers in Drug Discovery – How to Predict for Success in the Clinic. Registration is open!

Venue  Universitetshuset, Room IX, Biskopsgatan 3, Uppsala
Time  8 November 2018, 10am–4pm
Registration & Information  SciLifeLab Events
Contact  Kristian Sandberg, SciLifeLab

Biomarkers in Drug Discovery

Biomarkers have influence on understanding of disease mechanism, optimize the chance for successful patients’ selection and outcomes of clinical trials and thus may contribute to minimizing cost of a drug development. In drug discovery, the accompanying discovery of potential biomarkers and the subsequent development as tools to identify patients that can benefit from treatment and to demonstrate a pharmacological response to the exploratory drug are therefore of increasing importance. In this minisymposium, we gather international academic and industrial experts to review state-of-the-art and new initiatives. Please, take the chance to discuss your own project with the speakers during the day.

Preliminary Programme

10:00     Introduction
              Kristian Sandberg, SciLifeLab/DDD
              Anna Sandström, AstraZeneca

10:15    Biomarkers in 21st Century Drug Development
             Virginia Byers Kraus, MD, PhD (Durham, North Carolina, US)

11:00    Transforming Drug Research and Development with Genomics
             Carolina Haefliger, MD, AstraZeneca VP, Head of CVRM Precision Medicine

11:30    Turning a biomarker candidate into a diagnostic for clinical use
             Joachim Reischl, AstraZeneca VP, Head of Policy, Portfolio & Externalisation

12:00    Lunch and mingle

13:00    Rigging diagnostics for new predictive biomarkers – the Genomic Medicine Sweden initiative
             Johan Botling, MD, PhD, Uppsala University

13:30    Truly Translational – helping the small to think big. Biomarker strategies for SME’s
             Karin von Wachenfeldt, PhD, CEO Truly Translational Sweden AB

14:00    SCAN-B: transcriptome profiling of early breast cancer for identification of patients that may benefit from treatment
             Åke Borg, PhD, Lund University

14:30    Coffee and mingle

15:00     Biomarkers in the development of KAND567 in acute myocardial infarction
              Niclas Brynne, PhD, Chief Development officer at Kancera

15:30     Panel discussion and concluding remarks

Arr. SciLifeLab Drug Discovery and Development platform, AstraZeneca